8 Sources of evidence considered by the Committee

8 Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by Southampton Technology Assessment Centre:

  • Cooper K, Hartwell D, Copley V et al. Bortezomib for induction therapy in multiple myeloma before high dose chemotherapy and autologous stem cell transplantation: A Single Technology Appraisal. SHTAC. May 2013

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to give their expert views. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I. Manufacturer/sponsor:

  • Janssen

II. Professional/specialist and patient/carer groups:

  • Myeloma UK

  • South Asian Health Foundation

  • British Society of Haematology

  • Cancer Research UK

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians

  • UK Myeloma Forum

III. Other consultees:

  • Department of Health

  • Welsh Government

IV. Commentator organisations (did not provide written evidence and without the right of appeal):

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Healthcare Improvement Scotland

  • Medicines and Healthcare products Regulatory Agency

  • Celgene

  • Pfizer

  • National Cancer Research Institute

  • Southampton Health Technology Assessment Centre (SHTAC)

  • National Institute for Health Research Health Technology Assessment Programme

  • National Collaborating Centre for Cancer

C. The following individuals were selected from clinical specialist and patient expert nominations from the consultees and commentators. They gave their expert personal view on bortezomib by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr Jenny Bird, Consultant Haematologist, nominated by Royal College of Pathologists and British Society of Haematology – clinical specialist

  • Professor Kwee Yong, Consultant Haematologist, nominated by UK Myeloma Forum, Royal College of Pathologists and British Society of Haematology – clinical specialist

  • Eric Low, Chief Executive, nominated by UK Myeloma Forum – patient expert

  • Stuart Fullerton, nominated by UK Myeloma Forum – patient expert

D. Representatives from the following manufacturer/sponsor attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Janssen

  • National Institute for Health and Care Excellence (NICE)